MQMingming Qi

Mingming Qi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mingming Qi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Fanhua Zeng

    Department of Obstetrics Zhuzhou Central Hospital and The Affiliated Zhuzhou Hospital Xiangya Medical College CSU Zhuzhou China

    1 shared publication
  • Huan Chen

    Department of Obstetrics and Gynecology, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People’s Republic of China

    1 shared publication
  • Huimin Lai

    Department of Obstetrics Zhuzhou Central Hospital and The Affiliated Zhuzhou Hospital Xiangya Medical College CSU Zhuzhou China

    1 shared publication
  • Jing Zhang

    Department of Obstetrics Zhuzhou Central Hospital and The Affiliated Zhuzhou Hospital Xiangya Medical College CSU Zhuzhou China

    1 shared publication
  • Jingnan Liao

    Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control Changsha Hospital for Maternal and Child Health Care Affiliated to Hunan Normal University Changsha China

    1 shared publication
  • Jinjin Wang

    Department of Gynaecology, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan, China

    1 shared publication

Latest Publications

  • Open Access

    MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway

    by Jingnan Liao, Huan Chen, Mingming Qi, Jinjin Wang, Mingyuan Wang

    Endometrial cancer (EC) is a gynecological malignant tumor characterized by high incidence. EC occurrence and development are regulated by numerous molecules and signal pathways. There is a need to explore key regulatory molecules to identify potential therapeutic targets to reduce the incidence of EC. Treatment by targeting a single molecule is characterized by poor efficacy owing to the development of resistance and significant side effects. The current study explored potential candidates in EC by integrating bioinformatics analysis and in vivo and in vitro experimental validation to circumvent the limitation of low efficacy of currently used molecules. Molecular dynamics simulations provide details at the molecular level of intermolecular regulation. In the current study, MLLT11 and TRIL were identified as important regulatory molecules in EC. The two molecules formed a heteromultimer by binding to AKT protein, which induced its phosphorylation of threonine at position 308. Ultimately, the complex stimulates PI3K/AKT/mTOR signaling pathway, a pivotal pathway in tumors. The findings of the current study show a novel complex, MLLT11-TRIL, which can act as AKT protein agonist, thus inducing activity of PI3K/AKT/mTOR signaling pathway. Targeting MLLT11 and TRIL simultaneously, or blocking the formation of the MLLT11-TRIL complex, can abrogate progression of EC.


  • Pregestational screening of hereditary deafness genes carriers in 10,684 normal pregnant women in Zhuzhou, China

    by Mingming Qi, Huimin Lai, Lili Xu, Fanhua Zeng, Jing Zhang, Kaili Xie

    Background: Mutations in genes associated with deafness differ between ethnic groups and regions in China. In this study, we investigated the genes associated with deafness in pregnant women to analyze the distribution of mutations leading to deafness in Zhuzhou, China.Methods: A total of 10,684 pregnant women were enrolled in this study. DNA samples were collected to detect the 14 common mutations in deafness genes (at 108 sites).Results: Prevalence of mutations in deafness genes in pregnant women with normal hearing in Zhuzhou was 4.92% (526/10,684). Among these 526 pregnant women with deafness gene mutations, the frequencies of mutated GJB2, GJB3, SLC26A4, and mtDNA 12S rRNA were 40.11, 7.22, 40.68, and 11.98%, respectively. The hotspots for mutations in the deafness genes were: c.235delC in GJB2 (31.18%), c.919‐2A > G in SLC26A4 (18.44%), c.299_300delAT in GJB2 (5.70%), m.7444G > A in mtDNA 12S rRNA (5.70%), c.1229C > T in SLC26A4 (5.51%), m.1555A > G in mtDNA 12S rRNA (5.32%), accounting for 71.85%. Moreover, husbands of the 526 pregnant women who carried the deafness gene mutations were also included in the analysis to detect deafness gene mutations. Among the 526 husbands, 23 husbands carried mutations in deafness genes, accounting for 4.37%. The deafness gene mutations of the husbands and pregnant wives were not the same. In addition, the results of the neonatal follow‐up hearing tests were all normal.Conclusion: Our study identified the prevalence of mutations in GJB2, SLC26A4, mtDNA 12S rRNA, and GJB3 genes in pregnant women from Zhuzhou, China.